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Conclusion: Higher TSL per patient and per lesion were associated with increased 5-
year TLR and stent thrombosis rates.
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Background: The Charlson Comorbidity Index (CCI) is a useful tool for assessing the
importance of major comorbidities for clinical management and outcome of patients
in different medical fields. We aimed to evaluate the impact of CCI on early and late
clinical outcomes in a large population of patients treated with one type of drug eluting
stent (DES) in daily PCI practice.
Methods: We enrolled 3067 consecutive patients in 125 centers worldwide. All patients
were treated with Nobori DES. Follow-up was scheduled at 1 and 6 months and yearly
up to five years. The information pertinent to the CCI score was obtained before the
procedure. Data were captured electronically and their quality was extensively
monitored. An independent clinical event committee adjudicates all adverse events.
The primary endpoint was target lesion failure (TLF), a composite of cardiac death,
target vessel related MI and target lesion revascularization (TLR).
Results: For the 3067 enrolled patients, CCI scores were: CCI0=787; CCI1=1382;
CCI2=595 and CCI≥3=303. Patients with a CCI≥2 were significantly older, more often
female, had a higher incidence of diabetes, renal failure, chronic lung disease, prior
cerebrovascular disease or cancer and were more frequently admitted with ACS as
compared to patients with a CCI<2. QCA analysis of target lesions revealed
significantly smaller RVD pre- and post-procedure in CCI≥2 as compared to CCI<2.
TLF rates at 2 years were 2.9%, 3.7%, 7.1% and 12.9% in CCI0, 1, 2 and ≥3 groups.
Those differences were driven by cardiac death (0.6%, 0.7%, 3.0% and 5.3%; p<0.001)
and TLR (1.5%, 2.6%, 3.5% and 7.3%: p<0.001). Target vessel related MI (1.1%, 1.4%,
1.5% and 3.3%) and stent trombosis rates (0.3%, 0.9%, 1.2% and 1.3%) were not
significantly different.
Conclusion: The CCI was strongly correlated with the occurrence of major adverse
events at two year follow-up. This was particularly obvious for cardiac death and TLR
but less for target vessel related MI and stent thrombosis. CCI score may be of use to
better account for confounding factors in PCI registries, as well as to help optimize
treatment in selected high risk patients.
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Background: There is limited information on the use of second generation drug-eluting
stents in saphenous vein graft (SVG) lesions. In the present study we examined the
angiographic and clinical outcomes after implantation of the Xience V everolimus-
eluting stent (Abbott Vascular, Santa Clara, California) in SVG lesions.
Methods: The SOS-Xience study is a single-arm prospective study that enrolled 40
consecutive patients undergoing stenting of de novo SVG lesions. Patients were asked
to return for clinical and angiographic follow-up at 12 months. The primary endpoint
was binary in-segment restenosis (defined as >50% minimum lumen diameter stenosis
at the target SVG segment).
Results: Mean patient age was 67±7 years and 95% were men. The indications for
stenting included acute coronary syndrome (n=19, 48%) and stable angina (n=15,
38%). The mean SVG age was 11±7 years. An everolimus-eluting stent was
successfully implanted in all cases. Mean stent diameter and length were 3.0±0.46 and
18±6 mm, respectively. An embolic protection device was used in all cases (53%
Filterwire, 8% Spider, 40% Proxis). Follow-up angiography was performed in 27
patients (68%), of whom 4 patients (15%) had in-stent restenosis and required repeat
revascularization. In-stent restenosis was focal in all 4 lesions (3 of 4 were ostial
lesions).The median late loss was 0.52 mm (interquartile range 0.36, 0.92). The 12-
month incidence of major adverse cardiac events was 44% (n=17), mortality was 18%
(n=7), the incidence of acute myocardial infarction was 8% (n=3), and the incidence
of repeat revascularization was 30% (10 patients: 4 required target lesion
revascularization, 2 required revascularization of a different lesion in the target SVG
and 4 required revascularization of another vessel).
Conclusion: Use of the Xience V everolimus-eluting stent in de novo SVG lesions is
associated with low rates of angiographic restenosis and target lesion revascularization.
Patients undergoing SVG stenting have high risk for adverse clinical events during the
first year post stenting.
TCT-220
Efficacy and Saftey of 38 mm Long Stent Treatment for Diffuse Coronary
Disease: A Multicenter Evaluation by Angiography and OCT Analysis at One
Year After Implantation
Giuseppe Sangiorgi1, Fabiana Rollini1, Ahmed Rezq2, 1, Enrico Romagnoli3, Luigi
Politi1, Giuseppe Biondi Zoccai1, Alessandro Aprile1, Raffaella Marzullo1, Chiara
Leuzzi1, Maria Grazia Modena1, Antonio Colombo4
1Division of Cardiology, University of Modena and Reggio Emilia, Modena, Italy;
2Department of Cardiology, Ain Shams University, Cairo, Egypt; 3Department of
Cardiology, Policlinico Casilino, Rome, Italy; 4Cardiac Cath Lab, Emo Centro
Cuore Columbus Milan, Milan, Italy
Background: Very long lesions treatment usually contemplates the use of DES but
the implantation of multiple overlapping DES for diffuse disease increases the risk of
restenosis and stent thrombosis.
Methods: We prospectively evaluated the performance of 38mm-long DES in terms
of feasibility, efficacy and safety in elective patients undergoing stent implantation for
de novo diffuse (>33 mm) coronary disease. Endpoint of the study was the occurrence
of MACE (cardiac death, myocardial infarction, TLR and stent thrombosis at one year
FU). Secondary endpoints were OCT struts coverage, and malapposed struts at follow-
up.
Results: 68 pts with 79 lesions were enrolled, 83.8% male, mean age of 67.2 ±10 yrs.
All 79 lesions were type C, 23.5% C3. Lesions were treated with Taxus Libertè®, 14
with Endeavor Resolute®, and 10 with Xience® stents all post-dilated at high
atmosphere (>20 atm) with NC balloons. Mean stent size was 3.0±0.2, mean stent per
lesion was 1.1, mean stent length was 42.18 mm. No adverse in-hospital events were
observed. Mean follow-up of 8.2±3.7 months was done for all pts. No MACE but 2
not cardiac deaths (2.9%) occurred, no TLR detected. OCT was randomly performed
in 5 patients of each group at 8 mo FU angiography. Mean neointimal thickness was
140±72 μm, 223±107 μm and 254.5±82.5 μm and percentage of neointimal hyperplasia
was 15.7±9.4%, 20.7±11.9%, and 30.7±9.4% for the Resolute®, Taxus Libertè®, and
Xience® groups respectively, with a significant difference between Resolute® and the
other 2 groups (P= 0.0001 with Taxus®, P=0.024 with Xience®). Percentage of
IIIb+IV stent struts were 15.7%, 9.89%, and 0.87% of total struts analysed. Frames
with RUTTS > 30% were 23.1%, 16.2%, and 1.3% of total analyzed for Resolute®,
Taxus Libertè®, and Xience® groups respectively with a significant difference between
Xience® and the other 2 groups (P=0.0001 for both Resolute® and Taxus®)
Conclusion: Dedicated 38mm-long DES for treatment of complex diffuse disease can
be achieved with high success rate and excellent mid term safety profile. OCT analysis
revealed that second generation stents may perform significantly better than first
generation in terms of safety parameters.
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Long-term Safety and Effectiveness of Drug Eluting Stents Compared to Bare
Metal Stents in Non ST Elevation Myocardial Infarction: Findings from the
Guthrie Health Off-Label STent (GHOST) Registry
Sudhakar Sattur, Pam Orshaw, Judy Boura, Kishore Harjai
Guthrie- Robert Packer Hospital, Sayre, PA
Background: The long-term safety and effectiveness of drug eluting stents (DES)
versus bare metal stents (BMS) in non ST-segment elevation myocardial infarction
(NSTEMI) beyond 2 years after percutaneous coronary intervention (PCI) is unknown.
Methods: We studied 674 NSTEMI patients who underwent successful PCI with DES
(n=323) or BMS (n=351). The primary study end-points were time to occurrence of
death or non-fatal recurrent myocardial infarction, and stent thrombosis. Secondary
end-points included time to occurrence of target vessel revascularization (TVR) and
any major adverse cardiovascular event (MACE, defined as the composite of death,
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myocardial infarction, stent thrombosis, TVR).
Results: The DES and BMS groups were well matched except that DES patients
received dual antiplatelet therapy for a longer duration and had smaller final vessel
diameter. In survival analysis, at a mean follow-up of 1333 ± 659 days after PCI, the
DES group had similar incidence of death/myocardial infarction (24 vs 27%, log rank
p=0.23) and stent thrombosis (4.0 vs 2.6%, p=0.18) as the BMS group. The DES
patients had lower incidence of TVR (8.1 vs 17%, p=0.0018) but similar MACE (26
vs 37%, p=0.31). In multivariable analysis, DES vs BMS implantation showed no
significant impact on death/myocardial infarction [adjusted hazards ratio (HR) 1.0,
95% confidence intervals (CI) 0.7-1.4], stent thrombosis (HR 1.7; CI 0.7-4.0), or
MACE (HR 0.8; CI 0.6-1.1). However, TVR was lower in the DES group (HR 0.4; CI
0.3-0.7).
Conclusion: In patients presenting with NSTEMI, DES implantation appears to be as
safe as BMS implantation at long-term follow up.
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Background: There were no published data regarding the clinical efficacy and safety
of second generation drug-eluting stent (everolimus-eluting stent, EES) following
primary percutaneous coronary intervention (PCI) in ST-elevation myocardial
infarction (STEMI). We evaluated the one-year outcome of everolimus-eluting stent
versus to 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES)
and 2nd generation (zotarolimus-eluting stent) drug-eluting stents(DES) for the
treatment of STEMI.
Methods: A prospective, open-labeled, multi-center cohort has been performed at 4
centers in Korea. All patients will be clinically followed-up for two years. The primary
endpoint was major adverse cardiac event (MACE): the composite of cardiac death
(CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1
year. Stent thromboses (ST) by ARC definition were analyzed.
Results: Total 797 patients (EES=197, ZES=203, SES=203, PES=194) who were
completed more than one year were analyzed. One-year MACE were 2.0%, 5.9%,
3.4% and 5.7% in EES-, ZES-, SES- and PES-group, respectively (p=ns). Cardiac
death was 1.0%, 2.5%, 1.5% and 1.0% in EES-, ZES-, SES- and PES-group,
respectively (p=ns). ST was 0%, 2.0%, 2.0% and 2.0% in EES-, ZES-, SES- and PES-
group, respectively (p=ns).
Clinical events at 12 months and stent thrombosis
EES : everolimus-eluting stent, ZES : zotalimus-eluting stent, SES : sirolimus-
eluting stent, PES : paclitaxel-eluting stent, MACE : major adverse cardiac event,
MI : myocardial infarctin, TLR : target lesion revascularization
Conclusion: Campared to 1st and 2nd generation DES (SES and PES, ZES), EES
showed similar one-year clinical outcomes in terms of MACE in patients with STEMI
following primary PCI and no stent thrombosis.
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Background: The concept and possible benefit of complete revascularisation of all
detected lesions in patients with multivessel disease during one PCI procedure using
drug eluting stents (DES) is under debate. We compared long term clinical outcomes
of complete and incomplete revascularisation in patients with multivessel disease when
treated with a new generation DES coated only abluminally with biodegradable
polymer and Biolimus A9.
Methods: Among 3067 consecutive patients treated with Nobori DES, and enrolled
in NOBORI2 study, 1788 patients had multivessel disease out of which 593 underwent
complete revascularization (complete-PCI) and 1195 received treatment of most critical
lesions (incomplete-PCI). The primary endpoint of the study was target lesion failure
(TLF), a composite of cardiac death, target vessel related MI and target lesion
revascularization (TLR) at 1 year. Data are entered in an electronic database; all adverse
events are adjudicated by an independent clinical event committee and all angiograms
are analyzed by an independent corelab.
Results: Complete-PCI patients were younger and had less often previous CABG,
hypertension and ACS. Number of diseased vessels and detected lesions was
significantly lower in the complete-PCI group but the number of treated vessels and
stents implanted was significantly higher. Lesion complexity was similar in both groups
with more thrombotic lesions in patients with incomplete-PCI. Among QCA assessed
parameters, lesions were shorter with lower diameter stenosis pre-procedure in
complete-PCI group. At 2 year follow-up TLF rate was slightly higher in the complete-
PCI group (6.6% vs 5.5%; p=0.4) while non-TVR rate was lower (2.2% vs 5.6%;
p<0.001). Stent thrombosis was low in both groups (1.0% vs 1.1% incomplete-PCI;
p=NS).
Conclusion: Despite higher number of stents implanted in the complete-PCI group,
TLF was comparable with the incomplete-PCI group at 2 years. Therefore selective
revascularization strategy of the most critical lesions (followed by deferred
revascularization of some non-treated lesions) in higher risk patients is safe and results
in a favorable outcome.
TCT-224
Coating irreguralities of drug-eluting stents as assesed by scanning electron
microscopy
Takeshi Ijichi, Gaku Nakazawa
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Background: Implantation of drug eluting stents (DES) tends to be implanted in
complex lesion compared with bare metal stents era. Preservation of integrity of
polymer coating in these complex lesions is an important.
Methods: Taxus LibertéTM, Endeavor SprintTM, Xience VTM, Cypher SelectTM
and NoboriTM DES (five samples of each) were explored by scanning electron
microscopy (SEM) following expansion at nominal pressure. In addition to simple
expansion, a part of samples were tasked through the 5 or 6 French catheter with a
parallel wire in order to stimulate the injury. We classified DES coating damage into
four groups which were irregularities (Type I), cracks (Type II), craters with metal
exposure (Type III) and webbings (Type IV). Each DES showed specific feature of
abnormalities in polymer coating such as webbing in Taxus LibertéTM, craters in
Endeavor SprintTM and minor cracks in NoboriTM.
Results: After the injuries, craters with metal exposure were slightly increased in
NoboriTM, Xience VTM, while it was largely increased in Endeavor SprintTM. The
damage of polymer coating by the creation of injury was minimal Taxus LibertéTM.
The craters with metal exposure were seen in all types of DES. Among them, the
incidence of areas with bare metal exposure was particularly low in NoboriTM, Xience
VTM and Cypher SelectTM. Endeavor SprintTM showed the largest metal exposure
with scratch. Webbings of the coating were found in Taxus LibertéTM, while they were
not seen in Endeavor SprintTM.
The incidence of coating abnormality in all population
Conclusion: The incidence of various coating irregularities in different types of DES
varied widely. These data give us insight into the choice of DES especially in complex
lesions.
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Background: Randomized clinical trials showed safety and efficacy of everolimus-
eluting stents in selected patient populations. However, since the approval of
second-generation stents in the US, limited data are available with regard to their safety
and efficacy in unselected, consecutive patients.
Methods: Consecutive patients at Washington Hospital Center who underwent
coronary artery stent implantation with Xience, Taxus or Cypher stents were analyzed.
Patients who received other stent types were excluded. Analyzed clinical end points
were death, TLR, definite stent thrombosis (ST), and MACE (death, QWMI, or TLR)
at 1 year.
Results: A total of 5983 patients received DES. Xience patients had higher rates of
hypertension (89% vs. 86% vs. 85% respectively; p=0.003) and diabetes (40% vs. 35%
vs. 35%; p=0.03) but lower rates of family history of CAD (47% vs. 53% vs. 52%;
p=0.008) as compared with Cypher and Taxus. Nearly half of the patients had PCI for
unstable angina (51% vs. 43% vs. 45%, p <0.001) and treated lesions were more likely
to be Type C among Xience patients (47% vs. 21% vs. 23%; p <0.001). Unadjusted 1-
year MACE (8.1% vs. 9.6% vs. 11.2%) and all-cause mortality (3.4% vs. 4.8% vs.
6.9%) were significantly lower for Xience patients compared with Taxus but not to
Cypher patients. (Figure) Definite ST and TLR rates were non-significantly lower for
Xience patients as compared with Cypher or Taxus patients. (Figure) After adjusting
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